Telesis Bio (NASDAQ:TBIO) Shares Up 27.3% – Should You Buy?

Telesis Bio, Inc. (NASDAQ:TBIOGet Free Report)’s share price was up 27.3% on Monday . The company traded as high as $0.42 and last traded at $0.42. Approximately 445 shares changed hands during trading, a decline of 91% from the average daily volume of 4,751 shares. The stock had previously closed at $0.33.

Telesis Bio Stock Performance

The stock has a market capitalization of $756,420.00, a price-to-earnings ratio of -0.01 and a beta of 1.64. The firm has a fifty day moving average of $0.37 and a 200-day moving average of $1.41.

Telesis Bio Company Profile

(Get Free Report)

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.

See Also

Receive News & Ratings for Telesis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesis Bio and related companies with MarketBeat.com's FREE daily email newsletter.